Literature DB >> 6344785

Effect of growth phase on the bactericidal action of chloramphenicol against Haemophilus influenzae type b and Escherichia coli K-1.

W E Feldman, N S Manning.   

Abstract

The bactericidal action of chloramphenicol against six Haemophilus influenzae type b isolates and six Escherichia coli K-1 isolates was compared. Cells were grown in antibiotic-free medium into the late-stationary and mid-exponential phases of growth, and inocula of 10(5) to 10(6) cells per ml were added to fresh media containing 1 or 10 micrograms of chloramphenicol per ml for H. influenzae isolates, 80 micrograms of chloramphenicol per ml for E. coli isolates, or no chloramphenicol (antibiotic free). Quantitative kinetic studies indicated that each chloramphenicol concentration killed H. influenzae cells in the stationary phase of growth significantly more rapidly than it did those in the exponential phase of growth (P less than 0.001; analysis of variance). E. coli in either the stationary or the exponential phase were killed at the same rate by 80 micrograms of chloramphenicol per ml (P greater than 0.05). These results suggest that chloramphenicol may kill these organisms by different mechanisms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344785      PMCID: PMC184699          DOI: 10.1128/AAC.23.4.551

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis.

Authors:  W E Feldman
Journal:  J Pediatr       Date:  1976-04       Impact factor: 4.406

2.  A comparison of chloramphenicol and ampicillin as bactericidal agents for Haemophilus influenzae type B.

Authors:  D C Turk
Journal:  J Med Microbiol       Date:  1977-02       Impact factor: 2.472

3.  Kanamycin and gentamicin treatment of neonatal sepsis and meningitis.

Authors:  M J Chang; M Escobedo; D C Anderson; L Hillman; R D Feigin
Journal:  Pediatrics       Date:  1975-11       Impact factor: 7.124

4.  Central nervous system chloramphenicol concentration in premature infants.

Authors:  L M Dunkle
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

5.  Bactericidal and bacteriostatic action of chloramphenicol against memingeal pathogens.

Authors:  J J Rahal; M S Simberkoff
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

6.  Effect of ampicillin and chloramphenicol alone and in combination on ampicillin-susceptible and -resistant Haemophilus influenzae type B.

Authors:  F S Cole; R S Daum; L Teller; D A Goldmann; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1979-03       Impact factor: 5.191

7.  The necessity for monitoring chloramphenicol levels when treating neonatal meningitis.

Authors:  S B Black; P Levine; H R Shinefield
Journal:  J Pediatr       Date:  1978-02       Impact factor: 4.406

8.  Clinical studies of a new latex particle agglutination test for detection of Haemophilus influenzae type b polyribose phosphate antigen in serum, cerebrospinal fluid, and urine.

Authors:  E D Shaw; R J Darker; W E Feldman; B M Gray; L L Pifer; G B Scott
Journal:  J Clin Microbiol       Date:  1982-06       Impact factor: 5.948

9.  Bactericidal activity of the combinations of gentamicin with clindamycin or chloramphenicol against species of Escherichia coli and Bacteroides fragilis.

Authors:  J Klastersky; M Husson
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

  9 in total
  2 in total

1.  Effects of antibiotics and a proto-oncogene homolog on destruction of protein translocator SecY.

Authors:  Johna van Stelten; Filo Silva; Dominique Belin; Thomas J Silhavy
Journal:  Science       Date:  2009-08-07       Impact factor: 47.728

2.  Effect of changes in the osmolarity of the growth medium on Vibrio cholerae cells.

Authors:  A Lohia; S Majumdar; A N Chatterjee; J Das
Journal:  J Bacteriol       Date:  1985-09       Impact factor: 3.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.